Gene · 23600
Papers2,301
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,301
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Unmasking the enigma: A case of Fumarate Hydratase-deficient renal cell carcinoma. | Int J Surg Case Rep | 2023 | 37992668 | PubTator, text mining | PubMed |
| Radiotranscriptomics identified new mRNAs and miRNA markers for distinguishing prostate cancer from benign prostatic hyperplasia. | Cancer Med | 2023 | 37987209 | PubTator, text mining | PubMed |
| Malignant rhabdoid tumor of kidney in an adult patient with positive family history of rhabdoid tumor: A case report and review of literature. | Int J Surg Case Rep | 2023 | 37976714 | PubTator, text mining | PubMed |
| MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. | JCI Insight | 2023 | 37971875 | PubTator, text mining | PubMed |
| Biomarkers in renal cell carcinoma and their targeted therapies: a review. | Explor Target Antitumor Ther | 2023 | 37970211 | PubTator, text mining | PubMed |
| Rare urachal mucinous cystic tumor of low malignant potential with peritoneal pseudomyxoma: A case report. | Exp Ther Med | 2023 | 37941591 | PubTator, text mining | PubMed |
| mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy. | Virchows Arch | 2023 | 37938323 | PubTator, text mining | PubMed |
| Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review. | Diagn Pathol | 2023 | 37924117 | PubTator, text mining | PubMed |
| Bilateral Ureteral Nephrogenic Adenoma: An Unusual Mimicker of Malignancy. | Cureus | 2023 | 37916237 | PubTator, text mining | PubMed |
| Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing. | Curr Oncol | 2023 | 37887551 | PubTator, text mining | PubMed |
| Primary clear cell carcinoma of the vulva: A case report. | Gynecol Oncol Rep | 2023 | 37860082 | PubTator, text mining | PubMed |
| Design and evaluation of substrate-product analog inhibitors for racemases and epimerases utilizing a 1,1-proton transfer mechanism. | Methods Enzymol | 2023 | 37858537 | PubTator, text mining | PubMed |
| Analysis of enzyme reactions using NMR techniques: A case study with α-methylacyl-CoA racemase (AMACR). | Methods Enzymol | 2023 | 37858529 | PubTator, text mining | PubMed |
| Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer. | Cancer Cell Int | 2023 | 37858151 | PubTator, text mining | PubMed |
| Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT. | Virchows Arch | 2023 | 37845471 | PubTator, text mining | PubMed |
| Advances in the two-dimensional layer materials for cancer diagnosis and treatment: unique advantages beyond the microsphere. | Front Bioeng Biotechnol | 2023 | 37840663 | PubTator, text mining | PubMed |
| High Prognostic Value of 68Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry. | Diagnostics (Basel) | 2023 | 37835825 | PubTator, text mining | PubMed |
| Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives. | Diagnostics (Basel) | 2023 | 37835765 | PubTator, text mining | PubMed |
| Expression of nectin-4 in prostate cancer. | North Clin Istanb | 2023 | 37829757 | PubTator, text mining | PubMed |
| Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors. | Hum Pathol | 2023 | 37797754 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23600/papers?page=9